Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Cascadian Therapeutics Inc. buy stratec

Cascadian Therapeutics Inc.
Start price
€5.07
30.01.18 / 50%
Target price
€9.66
13.04.18
Performance (%)
78.29%
End price
€9.04
13.04.18
Summary
This prediction ended on 13.04.18 with a price of €9.04. With a performance of 78.29% the BUY prediction by stratec was a big success. stratec has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Cascadian Therapeutics Inc. - - - -
iShares Core DAX® 1,72 % 3,37 % 5,89 % 52,38 %
iShares Nasdaq 100 -4,56 % -4,24 % 21,39 % 72,45 %
iShares Nikkei 225® -7,12 % -11,87 % 42,36 % 57,58 %
iShares S&P 500 -0,89 % 1,69 % 19,49 % 62,15 %

Comments by stratec for this prediction

In the thread Cascadian Therapeutics Inc. diskutieren
Prediction Buy
Perf. (%) 78.29%
Target price 9.660
Change
Ends at 13.04.18

Cascadian Therapeutics is a Conviction Buy

31.01.2017


  • Seattle Genetics (NASDAQ:SGEN) has agreed to acquire Cascadian Therapeutics (NYSE:CASC) for $10 per share in cash, more than a 69% premium to yesterday's closing price of $5.90. Total consideration will be ~$614M.

  • Cascadian's lead candidate is tyrosine kinase inhibitor tucatinib, highly selective for growth factor receptor HER2 without significantly inhibiting EGFR which causes unwanted side effects.

  • SGEN has secured a financing commitment from Barclays and JPMorgan-Chase Bank for $400M. The balance will be funded with cash on hand.

  • The transaction should close this quarter




    • stratec 
    0
    Report Share
    30.01.18
    Prediction Buy
    Perf. (%) 78.29%
    Target price 9.660
    Change
    Ends at 13.04.18

    (Vom Mitglied beendet)

    stratec 
    0
    Report Share
    13.04.18